Analysts expect that Valeritas Holdings, Inc. (NASDAQ:VLRX) will report sales of $5.14 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Valeritas Holdings’ earnings. The highest sales estimate is $5.29 million and the lowest is $5.00 million. Valeritas Holdings reported sales of $4.89 million during the same quarter last year, which indicates a positive year-over-year growth rate of 5.1%. The firm is scheduled to announce its next earnings report on Wednesday, August 9th.

On average, analysts expect that Valeritas Holdings will report full year sales of $5.14 million for the current fiscal year, with estimates ranging from $21.84 million to $22.43 million. For the next fiscal year, analysts anticipate that the business will post sales of $28.04 million per share, with estimates ranging from $26.03 million to $30.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Valeritas Holdings.

Valeritas Holdings (NASDAQ:VLRX) last released its quarterly earnings results on Friday, May 12th. The company reported ($6.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.72) by $4.20. The business had revenue of $4.61 million for the quarter, compared to analysts’ expectations of $4.64 million.

A number of brokerages recently commented on VLRX. ValuEngine upgraded Valeritas Holdings from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. B. Riley restated a “buy” rating and set a $10.00 target price on shares of Valeritas Holdings in a report on Wednesday, May 17th. Finally, Cowen and Company started coverage on Valeritas Holdings in a report on Monday, April 17th. They issued an “outperform” rating for the company.

Valeritas Holdings (NASDAQ VLRX) opened at 6.7816 on Friday. The company’s market cap is $46.40 million. The firm’s 50-day moving average is $5.20 and its 200 day moving average is $18.96. Valeritas Holdings has a 12-month low of $4.51 and a 12-month high of $52.00.

COPYRIGHT VIOLATION WARNING: “Brokerages Expect Valeritas Holdings, Inc. (NASDAQ:VLRX) Will Announce Quarterly Sales of $5.14 Million” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/09/brokerages-expect-valeritas-holdings-inc-nasdaqvlrx-will-announce-quarterly-sales-of-5-14-million.html.

In other news, insider John Edward Timberlake acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, May 17th. The stock was acquired at an average price of $5.14 per share, for a total transaction of $25,700.00. Following the completion of the acquisition, the insider now owns 23,037 shares in the company, valued at $118,410.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders acquired 11,500 shares of company stock valued at $57,615. 1.20% of the stock is owned by corporate insiders.

An institutional investor recently bought a new position in Valeritas Holdings stock. HighTower Advisors LLC bought a new position in Valeritas Holdings, Inc. (NASDAQ:VLRX) during the first quarter, according to its most recent disclosure with the SEC. The fund bought 27,400 shares of the company’s stock, valued at approximately $195,000. HighTower Advisors LLC owned approximately 1.67% of Valeritas Holdings at the end of the most recent reporting period. Institutional investors own 11.65% of the company’s stock.

Valeritas Holdings Company Profile

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas Holdings (VLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Valeritas Holdings (NASDAQ:VLRX)

Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.